Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy

Although medical technology has improved the quality of life of HNSCC patients, their survival rate has not increased significantly, and their life and health continue to be threatened. With the help of modern medical technology, medical institutions can confirm the diagnosis of HNSCC patients in a timely manner, so as to take appropriate surgical treatment plans. However, surgery is difficult for patients with recurrent or metastatic HNSCC, and concurrent chemotherapy alone is not effective for HNSCC patients. Therefore, in this paper, the chemotherapy and immunotherapy of HNSCC patients were studied, and the following conclusions were drawn by detecting the peripheral blood lymphocytes of HNSCC patients. The NK cell (natural killer cell) index of healthy people was 6.64% higher than that of HNSCC patients. The CD4+/CD8+ ratio (CD4+ is inductive T cells and helper T cells, CD8+ is suppressor T cells and cytotoxic T cells) in HNSCC patients is in a downward trend during concurrent chemotherapy. Concurrent chemotherapy not only kills HNSCC cells, but also inhibits normal immune cells. The detection of peripheral blood lymphocytes of HNSCC patients has reference value for judging the immune function and curative effect of patients.

Authors

Institutions

Publication Details

Journal
SLAS TECHNOLOGY
Published
2025-05-03
DOI
https://doi.org/10.1016/j.slast.2025.100303
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy

Guodong Man, Jianli Wang
SLAS TECHNOLOGY
Head and Neck Cancer Studies
article

Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy

Guodong Man, Jianli Wang
article en

Abstract

Although medical technology has improved the quality of life of HNSCC patients, their survival rate has not increased significantly, and their life and health continue to be threatened. With the help of modern medical technology, medical institutions can confirm the diagnosis of HNSCC patients in a timely manner, so as to take appropriate surgical treatment plans. However, surgery is difficult for patients with recurrent or metastatic HNSCC, and concurrent chemotherapy alone is not effective for HNSCC patients. Therefore, in this paper, the chemotherapy and immunotherapy of HNSCC patients were studied, and the following conclusions were drawn by detecting the peripheral blood lymphocytes of HNSCC patients. The NK cell (natural killer cell) index of healthy people was 6.64% higher than that of HNSCC patients. The CD4+/CD8+ ratio (CD4+ is inductive T cells and helper T cells, CD8+ is suppressor T cells and cytotoxic T cells) in HNSCC patients is in a downward trend during concurrent chemotherapy. Concurrent chemotherapy not only kills HNSCC cells, but also inhibits normal immune cells. The detection of peripheral blood lymphocytes of HNSCC patients has reference value for judging the immune function and curative effect of patients.

SLAS TECHNOLOGYVol. 32
Gansu Provincial Hospital (CN)
Good health and well-being
Openalex Percentile: Top 88%
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Changes of peripheral blood lymphocyte population in patients with head and neck squamous cell carcinoma undergoing concurrent chemotherapy — Guodong Man, Jianli Wang · SLAS TECHNOLOGY (2025) | TGRS Research Map | TGRS